Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tim Knotnerus
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 62
- Beta
- 1.66
- Country
- BE
Financials
AGMB has only 3 quarterly periods on file — the charts below show the full history available.
Net Income
$-17.40MEBITDA
$-17.62MFree Cash Flow
$-13.18MEPS (diluted)
$-0.36Shares Outstanding (diluted)
48.74M+34.5%Operating Expenses
$17.12MCash & Debt
$116.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-62.55M | $-1.28 |
| 2024 | $0.00 | $-46.27M | $-1.26 |
| 2023 | $0.00 | $-11.39M | $-0.31 |
| 2022 | $0.00 | $-8.14M | $-0.22 |
Valuation
AGMBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Agomab to Participate in Upcoming Investor Conferences Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY.
View source ↗
Earnings
Wed, Mar 3(in 6 months)
Consensus estimate $-0.98 per share
Typical surprise -177.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.91 vs $1.18miss
- Thu, Apr 23$-45.69 vs $-0.52miss
- Wed, Feb 25$-0.36 vs $-0.52beat
Estimates and results for AGMB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.